Warrants	12 Months Ended
Dec. 31, 2021
Warrants [Abstract]
Warrants	Note 12 – Warrants The Company accounts for common stock warrants pursuant to applicable accounting guidance contained in ASC 815, "Derivatives and Hedging - Contracts in Entity's Own Equity" and makes a determination as to their treatment as either equity instruments or a warrant liability based on an analysis of the underlying warrant agreements. The following table sets forth the Company’s outstanding common stock warrants as of December 31, 2021: Issued Outstanding Exercise Price Expiration2016 Warrant Issuance 2,947,949 1,680,447 2.60 Feb 20222017 Warrant Issuance (1) 100,000 100,000 2.25 Mar 20222017 Warrant Issuance (2) 1,650,000 1,650,000 2.45 Nov 20222018 Warrant Issuance (2) 4,004,329 2,909,374 1.55 Jul 20232019 Warrant Issuance (3) 6,000,000 3,000,000 0.78 Oct 2024 9,339,821 (1)Issued in conjunction with an unsecured line of credit.(2)Warrants are subject to liability accounting.(3)Private Placement unregistered warrants exercisable six months following issuance. Equity classified warrants The 2016 and 2019 warrants share similar terms, and the exercise price of the warrant shares are subject to adjustment in the event of any stock dividends and splits, reverse stock splits, stock dividends, recapitalizations, reorganizations or similar transactions. The warrants will be exercisable on a “cashless” basis in certain circumstances, including in the event a registration statement is not in effect at time of exercise. The warrant agreements contain a clause specifying that in the event there is no effective registration in effect for the underlying warrant shares to be issued at time of exercise, in no circumstance will the Company be required to net cash settle the warrants. Based on the Company’s analysis of the terms and conditions of the warrants, the Company has concluded that they meet the conditions outlined in applicable accounting guidance to be classified as equity instruments. As a result, the Company has accounted for the exercise price paid by investors for purchase of the pre-funded warrants as additional paid in capital on the accompanying Consolidated Balance Sheet. Liability classified warrants The 2017 and 2018 warrants have alternative settlement provisions that, at the option of the holder, provide for physical settlement or if, at the time of settlement there is no effective registration statement, a cashless exercise as defined in the warrant agreement. Based on analysis of the underlying warrant agreement and applicable accounting guidance, the Company concluded that these registered warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. Accordingly, these warrants were classified in the accompanying Consolidated Balance Sheet as a current liability upon issuance and will be revalued at each subsequent balance sheet date. The fair value of the liability for common stock purchase warrants is estimated using the Black Scholes option pricing model based on the market value of the underlying common stock at the measurement date, the contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock. Based on the Black Scholes method the fair value of the Company’s warrants are as follows (in thousands): December 31 December 31, 2021 20202018 January and February Issuance Fair Value $ 1,355 $ 3,577 2017 May Issuance Fair Value 19 1,045 $ 1,374 $ 4,622 Twelve Months Ended December 31 2021 2020Change in Fair Value of common stock warrant liability (1) 3,248 (4,599) (1)The combined changes in fair value is reflected as income from change in the fair market value of common stock warrant liability.

Warrants

12 Months Ended

Dec. 31, 2021

Note 12 – Warrants The Company accounts for common stock warrants pursuant to applicable accounting guidance contained in ASC 815, "Derivatives and Hedging - Contracts in Entity's Own Equity" and makes a determination as to their treatment as either equity instruments or a warrant liability based on an analysis of the underlying warrant agreements. The following table sets forth the Company’s outstanding common stock warrants as of December 31, 2021: Issued Outstanding Exercise Price Expiration2016 Warrant Issuance 2,947,949 1,680,447 2.60 Feb 20222017 Warrant Issuance (1) 100,000 100,000 2.25 Mar 20222017 Warrant Issuance (2) 1,650,000 1,650,000 2.45 Nov 20222018 Warrant Issuance (2) 4,004,329 2,909,374 1.55 Jul 20232019 Warrant Issuance (3) 6,000,000 3,000,000 0.78 Oct 2024 9,339,821 (1)Issued in conjunction with an unsecured line of credit.(2)Warrants are subject to liability accounting.(3)Private Placement unregistered warrants exercisable six months following issuance. Equity classified warrants The 2016 and 2019 warrants share similar terms, and the exercise price of the warrant shares are subject to adjustment in the event of any stock dividends and splits, reverse stock splits, stock dividends, recapitalizations, reorganizations or similar transactions. The warrants will be exercisable on a “cashless” basis in certain circumstances, including in the event a registration statement is not in effect at time of exercise. The warrant agreements contain a clause specifying that in the event there is no effective registration in effect for the underlying warrant shares to be issued at time of exercise, in no circumstance will the Company be required to net cash settle the warrants. Based on the Company’s analysis of the terms and conditions of the warrants, the Company has concluded that they meet the conditions outlined in applicable accounting guidance to be classified as equity instruments. As a result, the Company has accounted for the exercise price paid by investors for purchase of the pre-funded warrants as additional paid in capital on the accompanying Consolidated Balance Sheet. Liability classified warrants The 2017 and 2018 warrants have alternative settlement provisions that, at the option of the holder, provide for physical settlement or if, at the time of settlement there is no effective registration statement, a cashless exercise as defined in the warrant agreement. Based on analysis of the underlying warrant agreement and applicable accounting guidance, the Company concluded that these registered warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. Accordingly, these warrants were classified in the accompanying Consolidated Balance Sheet as a current liability upon issuance and will be revalued at each subsequent balance sheet date. The fair value of the liability for common stock purchase warrants is estimated using the Black Scholes option pricing model based on the market value of the underlying common stock at the measurement date, the contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock. Based on the Black Scholes method the fair value of the Company’s warrants are as follows (in thousands): December 31 December 31, 2021 20202018 January and February Issuance Fair Value $ 1,355 $ 3,577 2017 May Issuance Fair Value 19 1,045 $ 1,374 $ 4,622 Twelve Months Ended December 31 2021 2020Change in Fair Value of common stock warrant liability (1) 3,248 (4,599) (1)The combined changes in fair value is reflected as income from change in the fair market value of common stock warrant liability.